Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$155.41 +1.4%	$159.16	$140.68 ▼ $169.99	$374.51B	0.47	7.74 million shs	10.35 million shs
MRNA Moderna	$27.72 +2.1%	$34.43	$26.32 ▼ $170.47	$10.72B	1.86	6.94 million shs	11.79 million shs
PFE Pfizer	$24.73 +0.8%	$26.00	$24.33 ▼ $31.54	$140.26B	0.61	39.24 million shs	41.78 million shs
REGN Regeneron Pharmaceuticals	$625.60 +1.4%	$681.52	$603.47 ▼ $1,211.20	$68.39B	0.27	679,610 shs	899,886 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-7.62%	-4.90%	-7.25%	+5.96%	-2.87%
MRNA Moderna	-4.20%	-19.76%	-12.27%	-34.68%	-74.28%
PFE Pfizer	-3.27%	-4.05%	-7.21%	-7.56%	-11.46%
REGN Regeneron Pharmaceuticals	-2.72%	-2.70%	-11.70%	-13.38%	-36.35%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JNJ Johnson & Johnson	4.704 of 5 stars	3.3	3.0	4.2	3.9	3.2	2.5	0.6
MRNA Moderna	4.353 of 5 stars	4.0	1.0	0.0	4.6	1.9	2.5	1.3
PFE Pfizer	4.9858 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
REGN Regeneron Pharmaceuticals	4.8202 of 5 stars	4.4	3.0	1.7	2.3	3.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	10.25% Upside
MRNA Moderna	2.04	Hold	$59.00	112.84% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	29.09% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$966.88	54.55% Upside

Current Analyst Ratings Breakdown

Latest MRNA, PFE, JNJ, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
4/2/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/31/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$1,100.00 ➝ $1,000.00
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$159.00 ➝ $171.00
2/19/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$88.82B	4.22	$12.77 per share	12.17	$29.69 per share	5.23
MRNA Moderna	$3.20B	3.35	N/A	N/A	$28.33 per share	0.98
PFE Pfizer	$63.63B	2.20	$3.88 per share	6.38	$15.81 per share	1.56
REGN Regeneron Pharmaceuticals	$14.20B	4.82	$41.08 per share	15.23	$268.50 per share	2.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$14.07B	$6.65	23.37	14.04	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.54	8.16	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	16.34	16.45	2.34	31.07%	16.32%	12.76%	4/29/2025 (Estimated)

Latest MRNA, PFE, JNJ, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/29/2025	N/A	REGN Regeneron Pharmaceuticals	$8.83	N/A	N/A	N/A	$3.40 billion	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
2/4/2025	Q4 24	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$4.96	3.19%	+5.43%	74.59%	63 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.96%	+2.50%	121.99%	16 Years
REGN Regeneron Pharmaceuticals	$0.88	0.14%	N/A	2.30%	N/A

Latest MRNA, PFE, JNJ, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.43	1.11	0.86
MRNA Moderna	N/A	3.67	3.62
PFE Pfizer	0.63	1.00	0.73
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
PFE Pfizer	68.36%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
PFE Pfizer	0.06%
REGN Regeneron Pharmaceuticals	7.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable

MRNA, PFE, JNJ, and REGN Headlines

Recent News About These Companies

Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?

April 2 at 10:30 AM | insidermonkey.com

Groupama Asset Managment Has $56.45 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 7:06 AM | marketbeat.com

Trexquant Investment LP Acquires 42,674 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 6:46 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Alliancebernstein L.P.

April 2 at 5:33 AM | marketbeat.com

Schroder Investment Management Group Sells 13,477 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 4:49 AM | marketbeat.com

WINTON GROUP Ltd Sells 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 4:07 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low on Analyst Downgrade

April 1 at 11:12 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,000.00 at JPMorgan Chase & Co.

April 1 at 10:56 AM | marketbeat.com

RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO

April 1 at 10:02 AM | youtube.com

Franklin Resources Inc. Has $1.46 Billion Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 7:09 AM | marketbeat.com

Cannell & Spears LLC Has $11.44 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:49 AM | marketbeat.com

Summit Financial LLC Has $7.50 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:39 AM | marketbeat.com

AIA Group Ltd Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:01 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,000.00 by Analysts at JPMorgan Chase & Co.

April 1 at 2:39 AM | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low After Analyst Downgrade

April 1 at 1:23 AM | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows

March 31 at 8:23 PM | finance.yahoo.com

Regeneron price target lowered to $1,000 from $1,100 at JPMorgan

March 31 at 5:55 PM | markets.businessinsider.com

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

March 31 at 10:10 AM | zacks.com

California Public Employees Retirement System Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 31 at 6:31 AM | marketbeat.com

RWA Wealth Partners LLC Acquires 18,027 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 31 at 6:14 AM | marketbeat.com

Allstate Corp Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 31 at 5:11 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

MRNA, PFE, JNJ, and REGN Company Descriptions

Johnson & Johnson NYSE:JNJ

$155.41 +2.16 (+1.41%)

Closing price 03:58 PM Eastern

Extended Trading

$154.95 -0.46 (-0.30%)

As of 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$27.72 +0.56 (+2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$26.50 -1.22 (-4.38%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$24.73 +0.19 (+0.77%)

Closing price 03:59 PM Eastern

Extended Trading

$24.47 -0.26 (-1.05%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals NASDAQ:REGN

$625.60 +8.60 (+1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$606.16 -19.44 (-3.11%)

As of 07:58 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time